Brought to you by 
Altea grants Lilly and Amylin PassPort rights
15 Apr 2009
Executive Summary
Drug delivery company Altea Therapeutics has granted Eli Lilly and its partner Amylin Pharmaceuticals exclusive worldwide rights to develop a transdermal patch formulation of their exenatide diabetes product using Altea's PassPort delivery system.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
- Transdermal
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Altea grants Lilly and Amylin PassPort rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice